Evidence map›Paper›PMID 30592084›Full record

ArticleAmerican journal of hematology2019

Hyperfiltration during early childhood precedes albuminuria in pediatric sickle cell nephropathy.

Jeffrey D Lebensburger, Inmaculada Aban, Brandi Pernell, Malgorzata Kasztan, Daniel I Feig, Lee M Hilliard, David J Askenazi

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in American journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07175051 (Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin), which is not on this map. Cited by 47 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07175051 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2026 to 2030Enrolled20ConditionsSickle Cell Anemia (HbSS, or HbSβ-thalassemia0), AlbuminuriaArmsEmpagliflozin (oral)
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Endothelin receptor antagonism in sickle cell disease: Is the time now?Canadian journal of physiology and pharmacology · 2026
    Review
  16. Management of Kidney Disease with Sickle Cell Disease.Journal of the American Society of Nephrology : JASN · 2025
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jeffrey D LebensburgerDivision of Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama.ORCID 0000-0001-5011-1022
Inmaculada AbanDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama.
Brandi PernellDivision of Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Malgorzata KasztanDivision of Cardio-Renal Physiology and Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Daniel I FeigDivision of Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, Alabama.
Lee M HilliardDivision of Pediatric Hematology Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
David J AskenaziDivision of Pediatric Nephrology, University of Alabama at Birmingham, Birmingham, Alabama.
University of Alabama at Birmingham · US

Funding

Chronobiology and Chronopharmacology to Prevent Sickle Cell NephropathyK23HL127100 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEBENSBURGER, JEFFREY D · 2015 to 2019
$916k
The role of endothelin-1 in tubular injury in sickle cell diseaseK99HL144817 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KASZTAN, MALGORZATA · 2019 to 2020
$306k
NHLBI NIH HHS K23 HL127100NHLBI NIH HHS K99 HL144817
6 · The paper itself

Abstract

backgroundIn patients with diabetes mellitus, hyperfiltration precedes the development of albuminuria. Pediatric sickle cell anemia (SCA) patients have a high prevalence of hyperfiltration and albuminuria during early childhood and adolescence. We tested the hypothesis that hyperfiltration precedes the development of albuminuria in a longitudinal pediatric SCA cohort.

methodsWe identified 91 participants with HbSS or SB0 thalassemia 5-21 years of age enrolled in a longitudinal sickle cell nephropathy cohort study who had a cystatin C measured during early childhood (4-10 years of age). Early hyperfiltration was defined as a mean eGFR >180 mL/min/1.73m

resultsPersistent albuminuria occurred more often and at an earlier age in participants with early hyperfiltration compared to those without early hyperfiltration (log-rank, P = .004). Participants who developed albuminuria have a significant increase in their eGFR during childhood (P = .003) as compared to participants who have not yet progressed to albuminuria (P = .26). For every 1 g/dL increase in hemoglobin, the hazard ratio for developing persistent proteinuria decreased by 0.56 (95% CI: 0.3, 1.06, P = .07).

conclusionHyperfiltration precedes the development of persistent proteinuria in pediatric SCA patients. Intervention strategies should target lowering eGFR during early childhood.

Indexed as

AlbuminuriaAnemia, Sickle CellGlomerular Filtration RateKidney DiseasesAdolescentAdultChildChild, PreschoolDisease-Free SurvivalFemaleHumansMaleProspective StudiesSurvival Rate

Identifiers

PMID30592084
PMCPMC6408275
OpenAlexW2908335803

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.